The best way to tell whether or not a piece of furniture on Amazon is good quality is by carefully considering the materials ...

Corcept Therapeutics (CORT) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings ...

Truist Financial analyst Joon Lee maintained a Buy rating on Corcept Therapeutics (CORT – Research Report) today. The company’s shares closed last Friday at $49.75. According to TipRanks ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Corcept Therapeutics (CORT – Research Report). The ...

Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) has received an average recommendation of “Buy” from the five brokerages that are covering the company, MarketBeat reports.

Canaccord Genuity maintained its Buy rating and $78.00 price target for NASDAQ:CORT, Corcept Therapeutics (NASDAQ:CORT). The firm highlighted the company's solid performance as the third quarter comes ...

Corcept Therapeutics (CORT) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings ...